Adjuvant radiotherapy in Stage II endometrial carcinoma

Is brachytherapy alone sufficient for local control?

Ima Paydar, Todd DeWees, Matthew Powell, David G. Mutch, Perry W. Grigsby, Julie K. Schwarz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To evaluate recurrence patterns and overall survival in patients treated with adjuvant radiation after surgical staging for Stage II endometrial carcinoma. Secondary goals include identification of prognostic factors for recurrence and toxicity assessment. Methods/Materials: The medical records of 41 patients treated with adjuvant radiotherapy at Washington University School of Medicine after surgical staging for endometrial cancer (total abdominal hysterectomy and bilateral salpingo-oophorectomy, peritoneal cytology, lymph node dissection) were reviewed. Nineteen were treated with a combination of external beam radiotherapy and vaginal brachytherapy (VB), and 22 patients were treated with postoperative VB alone. Median followup for all patients was 41months. Results: Median patient age was 59years (range, 42-87years). All tumors were of endometrioid histology. There were 20 Grade 1 tumors, 13 Grade 2 tumors, and 8 Grade 3 tumors. For all patients, the 5-year overall survival was 69.8%, and the 5-year recurrence-free survival was 89.0%. There was no statistically significant difference in overall survival (p= 0.510) or freedom from vaginal (p= 0.840), distant (p= 0.133), or any recurrence (p= 0.275) with respect to modality of treatment (external beam radiotherapy and VB vs. VB alone). There were no pelvic lymph node recurrences. In the univariate analysis, there were no risk factors influencing overall survival or recurrences. One patient experienced a toxicity requiring hospital admission. She was treated with pelvic external beam radiation plus brachytherapy. Conclusions: VB alone results in excellent local control for patients with Stage II endometrial cancer after surgical staging. Long-term toxicities are rare and more common in the group of patients who were treated with pelvic external beam plus brachytherapy.

Original languageEnglish (US)
Pages (from-to)427-432
Number of pages6
JournalBrachytherapy
Volume14
Issue number4
DOIs
StatePublished - Jul 1 2015
Externally publishedYes

Fingerprint

Adjuvant Radiotherapy
Brachytherapy
Endometrial Neoplasms
Recurrence
Survival
Neoplasms
Radiotherapy
Radiation
Ovariectomy
Lymph Node Excision
Hysterectomy
Medical Records
Cell Biology
Histology
Lymph Nodes
Medicine

Keywords

  • Adjuvant radiation
  • Endometrial adenocarcinoma
  • Gynecologic malignancy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Adjuvant radiotherapy in Stage II endometrial carcinoma : Is brachytherapy alone sufficient for local control? / Paydar, Ima; DeWees, Todd; Powell, Matthew; Mutch, David G.; Grigsby, Perry W.; Schwarz, Julie K.

In: Brachytherapy, Vol. 14, No. 4, 01.07.2015, p. 427-432.

Research output: Contribution to journalArticle

Paydar, Ima ; DeWees, Todd ; Powell, Matthew ; Mutch, David G. ; Grigsby, Perry W. ; Schwarz, Julie K. / Adjuvant radiotherapy in Stage II endometrial carcinoma : Is brachytherapy alone sufficient for local control?. In: Brachytherapy. 2015 ; Vol. 14, No. 4. pp. 427-432.
@article{3b2a29ebd19d48df919118d7edf280e2,
title = "Adjuvant radiotherapy in Stage II endometrial carcinoma: Is brachytherapy alone sufficient for local control?",
abstract = "Objective: To evaluate recurrence patterns and overall survival in patients treated with adjuvant radiation after surgical staging for Stage II endometrial carcinoma. Secondary goals include identification of prognostic factors for recurrence and toxicity assessment. Methods/Materials: The medical records of 41 patients treated with adjuvant radiotherapy at Washington University School of Medicine after surgical staging for endometrial cancer (total abdominal hysterectomy and bilateral salpingo-oophorectomy, peritoneal cytology, lymph node dissection) were reviewed. Nineteen were treated with a combination of external beam radiotherapy and vaginal brachytherapy (VB), and 22 patients were treated with postoperative VB alone. Median followup for all patients was 41months. Results: Median patient age was 59years (range, 42-87years). All tumors were of endometrioid histology. There were 20 Grade 1 tumors, 13 Grade 2 tumors, and 8 Grade 3 tumors. For all patients, the 5-year overall survival was 69.8{\%}, and the 5-year recurrence-free survival was 89.0{\%}. There was no statistically significant difference in overall survival (p= 0.510) or freedom from vaginal (p= 0.840), distant (p= 0.133), or any recurrence (p= 0.275) with respect to modality of treatment (external beam radiotherapy and VB vs. VB alone). There were no pelvic lymph node recurrences. In the univariate analysis, there were no risk factors influencing overall survival or recurrences. One patient experienced a toxicity requiring hospital admission. She was treated with pelvic external beam radiation plus brachytherapy. Conclusions: VB alone results in excellent local control for patients with Stage II endometrial cancer after surgical staging. Long-term toxicities are rare and more common in the group of patients who were treated with pelvic external beam plus brachytherapy.",
keywords = "Adjuvant radiation, Endometrial adenocarcinoma, Gynecologic malignancy",
author = "Ima Paydar and Todd DeWees and Matthew Powell and Mutch, {David G.} and Grigsby, {Perry W.} and Schwarz, {Julie K.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.brachy.2015.02.196",
language = "English (US)",
volume = "14",
pages = "427--432",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Adjuvant radiotherapy in Stage II endometrial carcinoma

T2 - Is brachytherapy alone sufficient for local control?

AU - Paydar, Ima

AU - DeWees, Todd

AU - Powell, Matthew

AU - Mutch, David G.

AU - Grigsby, Perry W.

AU - Schwarz, Julie K.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Objective: To evaluate recurrence patterns and overall survival in patients treated with adjuvant radiation after surgical staging for Stage II endometrial carcinoma. Secondary goals include identification of prognostic factors for recurrence and toxicity assessment. Methods/Materials: The medical records of 41 patients treated with adjuvant radiotherapy at Washington University School of Medicine after surgical staging for endometrial cancer (total abdominal hysterectomy and bilateral salpingo-oophorectomy, peritoneal cytology, lymph node dissection) were reviewed. Nineteen were treated with a combination of external beam radiotherapy and vaginal brachytherapy (VB), and 22 patients were treated with postoperative VB alone. Median followup for all patients was 41months. Results: Median patient age was 59years (range, 42-87years). All tumors were of endometrioid histology. There were 20 Grade 1 tumors, 13 Grade 2 tumors, and 8 Grade 3 tumors. For all patients, the 5-year overall survival was 69.8%, and the 5-year recurrence-free survival was 89.0%. There was no statistically significant difference in overall survival (p= 0.510) or freedom from vaginal (p= 0.840), distant (p= 0.133), or any recurrence (p= 0.275) with respect to modality of treatment (external beam radiotherapy and VB vs. VB alone). There were no pelvic lymph node recurrences. In the univariate analysis, there were no risk factors influencing overall survival or recurrences. One patient experienced a toxicity requiring hospital admission. She was treated with pelvic external beam radiation plus brachytherapy. Conclusions: VB alone results in excellent local control for patients with Stage II endometrial cancer after surgical staging. Long-term toxicities are rare and more common in the group of patients who were treated with pelvic external beam plus brachytherapy.

AB - Objective: To evaluate recurrence patterns and overall survival in patients treated with adjuvant radiation after surgical staging for Stage II endometrial carcinoma. Secondary goals include identification of prognostic factors for recurrence and toxicity assessment. Methods/Materials: The medical records of 41 patients treated with adjuvant radiotherapy at Washington University School of Medicine after surgical staging for endometrial cancer (total abdominal hysterectomy and bilateral salpingo-oophorectomy, peritoneal cytology, lymph node dissection) were reviewed. Nineteen were treated with a combination of external beam radiotherapy and vaginal brachytherapy (VB), and 22 patients were treated with postoperative VB alone. Median followup for all patients was 41months. Results: Median patient age was 59years (range, 42-87years). All tumors were of endometrioid histology. There were 20 Grade 1 tumors, 13 Grade 2 tumors, and 8 Grade 3 tumors. For all patients, the 5-year overall survival was 69.8%, and the 5-year recurrence-free survival was 89.0%. There was no statistically significant difference in overall survival (p= 0.510) or freedom from vaginal (p= 0.840), distant (p= 0.133), or any recurrence (p= 0.275) with respect to modality of treatment (external beam radiotherapy and VB vs. VB alone). There were no pelvic lymph node recurrences. In the univariate analysis, there were no risk factors influencing overall survival or recurrences. One patient experienced a toxicity requiring hospital admission. She was treated with pelvic external beam radiation plus brachytherapy. Conclusions: VB alone results in excellent local control for patients with Stage II endometrial cancer after surgical staging. Long-term toxicities are rare and more common in the group of patients who were treated with pelvic external beam plus brachytherapy.

KW - Adjuvant radiation

KW - Endometrial adenocarcinoma

KW - Gynecologic malignancy

UR - http://www.scopus.com/inward/record.url?scp=84930752646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930752646&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2015.02.196

DO - 10.1016/j.brachy.2015.02.196

M3 - Article

VL - 14

SP - 427

EP - 432

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 4

ER -